Skip to main content
Equibles
KURA logo

KURA · Kura Oncology, Inc.

Track KURA — free

Use KURA with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about KURA

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$11.15 +0.29 (+2.67%)
Market Cap
$966.11M
Shares
88.96M

Kura Oncology, Inc. Earnings Call Transcripts

Every quarterly earnings call for Kura Oncology, Inc. (KURA) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $14.11M −$57.43M '25 Q1 25-05-01 · $15.29M −$66.12M '25 Q2 25-08-07 · $20.75M −$74.12M '25 Q3 25-11-04 · $17.34M −$81.00M '25 Q4 26-03-05 ▲29.5% $18.27M −$73.33M '26 Q1 26-05-12 LATEST ▲36.5% $20.87M −$68.33M '26 Q2 26-08-12
Earnings call
FY26 · Q2
2026-08-12
Kura Oncology, Inc. Q2 FY2026 Earnings Call
Revenue
$20.87M
▲ 36.5% YoY
Diluted EPS
$-0.77
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-12
Kura Oncology, Inc. Q1 FY2026 Earnings Call
Revenue
$18.27M
▲ 29.5% YoY
Diluted EPS
$-0.83
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-05
Kura Oncology, Inc. Q4 FY2025 Earnings Call
Confident tone Comzifty commercial launch Combination strategy in AML Frontline AML development (COMET-017)
Revenue
$17.34M*
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Kura Oncology, Inc. Q3 FY2025 Earnings Call
Confident tone Ziftomenib regulatory progress (FDA/PDUFA) Differentiation vs. competitors (menin inhibitors) ASH data presentations and analyst event
Revenue
$20.75M
Diluted EPS
$-0.85
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Kura Oncology, Inc. Q2 FY2025 Earnings Call
Confident tone Ziftomenib AML Development (KOMET program) Frontline AML Expansion (Phase III) FTI Pipeline (KO-2806) and ESMO
Revenue
$15.29M
Diluted EPS
$-0.75
Rev · 2q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-01
Kura Oncology, Inc. Q1 FY2025 Earnings Call
Confident tone Ziftomenib NDA submission and regulatory progress Frontline AML combination program (KOMET-007/008/017) GIST / solid tumor expansion
Revenue
$14.11M
Diluted EPS
$-0.66
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-26
Kura Oncology, Inc. Q4 FY2024 Earnings Call
Confident tone Ziftomenib NDA submission and regulatory milestones Frontline AML development (KOMET-017) GIST expansion (KOMET-015)
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Kura Oncology, Inc. Q3 FY2024 Earnings Call
Confident tone Ziftomenib menin inhibitor program KOMET-007 combination trial in AML GIST solid tumor opportunity
Diluted EPS
$-0.63
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Kura Oncology, Inc. Q2 FY2024 Earnings Call
Confident tone Ziftomenib monotherapy in NPM1-mutant AML (KOMET-001) GIST / solid tumor expansion Frontline combination strategies (KOMET-007)
Diluted EPS
$-0.59
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-02
Kura Oncology, Inc. Q1 FY2024 Earnings Call
Confident tone Ziftomenib Breakthrough Therapy Designation and AML pipeline Ziftomenib combination trials (KOMET-007) Menin inhibitor pipeline expansion beyond leukemia
Diluted EPS
$-0.59
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-01-30
Kura Oncology, Inc. Q4 FY2023 Earnings Call
Confident tone Ziftomenib clinical data (KOMET-007) KO-2806 farnesyl transferase inhibitor (FIT-001) Ziftomenib regulatory / pivotal planning
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Kura Oncology, Inc. Q3 FY2023 Earnings Call
Diluted EPS
$-0.50
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Kura Oncology, Inc. Q2 FY2023 Earnings Call
Diluted EPS
$-0.53
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-10
Kura Oncology, Inc. Q1 FY2023 Earnings Call
Diluted EPS
$-0.50
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-23
Kura Oncology, Inc. Q4 FY2022 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Kura Oncology, Inc. Q3 FY2022 Earnings Call
Diluted EPS
$-0.53
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-03
Kura Oncology, Inc. Q2 FY2022 Earnings Call
Diluted EPS
$-0.52
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Kura Oncology, Inc. Q1 FY2022 Earnings Call
Diluted EPS
$-0.49
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-24
Kura Oncology, Inc. Q4 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Kura Oncology, Inc. Q3 FY2021 Earnings Call
Diluted EPS
$-0.50
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Kura Oncology, Inc. Q2 FY2021 Earnings Call
Diluted EPS
$-0.51
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Kura Oncology, Inc. Q1 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-02-24
Kura Oncology, Inc. Q4 FY2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Kura Oncology, Inc. Q3 FY2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Kura Oncology, Inc. Q2 FY2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-04
Kura Oncology, Inc. Q1 FY2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-02-25
Kura Oncology, Inc. Q4 FY2019 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Showing 1–27 of 27 earnings calls
Key facts CIK 1422143 CUSIP 50127T109 13F (30d) 221 filings 204 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)